Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Lyons

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
JACC. Cardiovascular Interventions|January 20, 2018
Dose-Dependent Cardioprotection of Moderate (32°C) Versus Mild (35°C) Therapeutic Hypothermia in Porcine Acute Myocardial InfarctionRajesh Dash, Yoshiaki Mitsutake, Wook Bum Pyun, et al.
Neurology and Therapy|June 24, 2023
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEMMitzi J Williams, Lilyana Amezcua, Angel Chinea, et al.
Advances in Therapy|November 21, 2024
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older PatientsYang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 29, 2022
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 EncephalitisEero Rissanen, Kelsey Carter, Steven Cicero, et al.
JAMA Network Open|September 28, 2022
Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical TrialPatrick Vermersch, Matthew Scaramozza, Seth Levin, et al.
CNS Drugs|January 19, 2020
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 StudyRobert T Naismith, Annette Wundes, Tjalf Ziemssen, et al.
Advances in Therapy|February 25, 2022
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 StudySibyl Wray, Florian Then Bergh, Annette Wundes, et al.
Radiology|April 16, 2009
Imaging gene expression in human mesenchymal stem cells: from small to large animalsJürgen K Willmann, Ramasamy Paulmurugan, Martin Rodriguez-Porcel, et al.
Circulation Research|July 24, 2012
Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activationMingxia Gu, Patricia K Nguyen, Andrew S Lee, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 27, 2025
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trialPeter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
JACC. Cardiovascular Interventions|January 20, 2018
Dose-Dependent Cardioprotection of Moderate (32°C) Versus Mild (35°C) Therapeutic Hypothermia in Porcine Acute Myocardial InfarctionRajesh Dash, Yoshiaki Mitsutake, Wook Bum Pyun, et al.
Neurology and Therapy|June 24, 2023
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEMMitzi J Williams, Lilyana Amezcua, Angel Chinea, et al.
Advances in Therapy|November 21, 2024
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older PatientsYang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 29, 2022
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 EncephalitisEero Rissanen, Kelsey Carter, Steven Cicero, et al.
JAMA Network Open|September 28, 2022
Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical TrialPatrick Vermersch, Matthew Scaramozza, Seth Levin, et al.
CNS Drugs|January 19, 2020
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 StudyRobert T Naismith, Annette Wundes, Tjalf Ziemssen, et al.
Advances in Therapy|February 25, 2022
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 StudySibyl Wray, Florian Then Bergh, Annette Wundes, et al.
Radiology|April 16, 2009
Imaging gene expression in human mesenchymal stem cells: from small to large animalsJürgen K Willmann, Ramasamy Paulmurugan, Martin Rodriguez-Porcel, et al.
Circulation Research|July 24, 2012
Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activationMingxia Gu, Patricia K Nguyen, Andrew S Lee, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 27, 2025
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trialPeter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, et al.
Pageof 4